Oncopeptides AB (publ), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the first quarter 2021.
“Oncopeptides now stands proudly among the few companies that have successfully navigated the long and difficult path from discovery to commercialization” says CEO, Marty J Duvall.
Financial overview January-March
Significant events January-March
Significant events after the reporting period
New dates for publication of the interim reports for Q2 and Q3 2021
Financial overview
(SEK thousand) |
2021 Jan-Mar |
2020 Jan-Mar |
2020 Jan-Dec |
Net sales |
19,355 |
– |
– |
Gross profit |
19,027 |
– |
– |
Gross margin |
98 % |
N/A |
N/A |
Operating loss |
-347,852 |
-296,876 |
-1,591,279 |
Loss before tax |
-347 852 |
-297,327 |
-1,592,442 |
Earnings per share before and after dilution (SEK) |
-3,45 |
-5.37 |
-25.57 |
Cash flow from operating activities |
-386,714 |
-312,841 |
-1,296,509 |
Cash and cash equivalents at the end of the period |
372,453 |
617,786 |
840,255 |
R & D costs/operating expenses, % |
49 % |
72 % |
54 % |
Conference call for investors, analysts and the media
Investors, financial analysts and media are invited to participate in a webcast with a Q&A session at 12:00 CEST. The event will be hosted by CEO, Marty J Duvall, CMO, Klaas Bakker and CFO, Anders Martin-Löf.
About Oncopeptides
Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO® (melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. In 2021 the second compound from the PDC platform, OPD5, is expected to enter clinical development.
Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass.
SOURCE Oncopeptides AB